Rezolute, Inc. Form 8-K Summary
Business Context and Reporting Period
On January 7, 2019, Rezolute, Inc. filed a Current Report on Form 8-K to disclose the entry into a Material Definitive Agreement. The filing details a Series AA Preferred Stock Financing arrangement entered into on the same date.
Key Financial Metrics and Transaction Details
- Aggregate Gross Proceeds: $25,000,000 (inclusive of a $1,500,000 exclusivity payment).
- Purchasers: Handok, Inc. and Genexine, Inc.
- Exclusivity Payment Credit: Each purchaser received a $750,000 credit applied to the purchase price.
- Conversion Price: The Offered Shares have an effective conversion price of $0.22 per share of common stock.
- Call Option: Purchasers may elect to purchase up to $10,000,000 worth of common stock by December 31, 2020, or upon a request for further financing, at a price of the greater of $0.29 per share or 75% of the 30-day volume-weighted average closing price.
The filing text does not provide clear values for revenue, profit, cash flow, margins, existing debt, or liquidity metrics as this is a transaction-specific report rather than a periodic financial statement.
Material Changes and Conditions
The transaction is subject to specific closing conditions that represent material changes to the company's governance and capital structure:
- Board Resignations: Closing is conditioned on the written resignations of Hoyoung Huh, David Welch, Tae Hoon Kim, and Samir Patel from the Board of Directors.
- Board Nomination Rights: Purchasers gain the right to nominate three members of the Board of Directors as long as they collectively hold at least 40% of the aggregate Offered Shares.
- Third-Party Waiver: Closing requires a waiver from XOMA (US) LLC regarding terms of a License Agreement dated December 6, 2018.
- Registration Rights: The Company agreed to file a registration statement within 60 days of closing and seek effectiveness within 90 days.
Outlook, Risks, and Contingencies
The financing is contingent upon the satisfaction of the conditions listed above. The Offered Shares will automatically convert upon an increase in authorized common stock following a stockholder meeting to amend the Certificate of Incorporation. The filing includes a Rule 135C notice stating that the securities have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption.
Key Facts for Investor Verification
- Confirmation of the resignation of the four specified board members.
- Receipt of the waiver from XOMA (US) LLC regarding the December 2018 License Agreement.
- Execution of the Certificate of Designations with the Delaware Secretary of State.
- Actual closing of the transaction and receipt of the $25,000,000 gross proceeds.
- Future filing of the registration statement for the resale of common stock issuable upon conversion.